Mike Briskin

Mike Briskin has worked in a variety of roles in the biotechnology industry since 2005. Mike began as a Senior Director at Merrimack Pharmaceuticals in 2005, then worked as a Consultant for Flagship Ventures and Theracrine in 2010. From 2013 to 2016, they were the VP of Jounce Therapeutics and President of IIO Consulting Inc. During this time, they also served as CSO ad interim for Xios Pharmaceuticals and Senior Advisor/SAB Chair for Obsidian Therapeutics. In 2020, they became CSO for Phenomic AI, Advisor for Catamaran Bio, and CSO ad interim and SAB member for Paretto Therapeutics.

Mike Briskin completed a Postdoctoral degree in Immunology from Stanford University between 1991 and 1993. Mike also attended University of California, Los Angeles, although no degree was obtained. In addition, Mike holds a Phd certification.